Background: Recently, the ETV6-NTRK3 gene fusion has been identified in both infantile fibrosarcoma and cellular mesoblastic nephroma. For both these tumors standard curative treatment has been primarily surgical with wide local excision. This has frequently involved radical and even mutilating surgery.
Procedure: This report discusses three infants with congenital tumors, two congenital fibrosarcomas, and one atypical congenital mesoblastic nephroma, not easily amenable to surgical intervention.
Results: All three were treated with pre-operative chemotherapy with excellent responses negating the need for amputation in two patients. In each patient, the ETV6-NTRK3 gene fusion was identified by reverse transcriptase-polymerase chain reaction (RT-PCR) in the tumor specimens.
Conclusions: Our findings suggest that the ETV6-NTRK3 gene fusion may underlie the distinctive biological properties of these tumors and may also indicate tumor chemosensitivity. In this group of patients pre-operative chemotherapy may abrogate the need for morbid surgical procedures.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mpo.10272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.
Cancer Sci
January 2025
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with poor prognosis and limited treatment options. While the majority of PDAC cases harbor KRAS mutations, approximately 8%-10% are KRAS wild-type (KRAS-WT). These KRAS-WT tumors often contain actionable mutations and gene fusions, making them more suitable for precision therapies.
View Article and Find Full Text PDFClinicopathologic characterization of secretory carcinoma of salivary gland.
World J Surg Oncol
October 2024
Department of Oral and Maxillofacial Surgery, First Hospital of Shanxi Medical University, No. 56 Jiefang South Road, Taiyuan, 030001, Shanxi Province, China.
Background: To investigate the clinicopathologic characteristics, therapeutic methods, and prognosis of secretory carcinoma of salivary gland (SCSG).
Methods: The clinicopathologic data of 13 patients with SCSG admitted to Shanxi Cancer Hospital from January 2018 to June 2023 were retrospectively analyzed, and a literature review was performed.
Results: A total of eight males and five females aged 22-78 years old were enrolled, and they commonly presented with painless masses in the parotid or submandibular gland.
Do not Judge a book by its Cover: A Secretory Carcinoma Arising from a Salivary Gland Heterotopia in Laterocervical lymph-node.
Head Neck Pathol
October 2024
Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, Unit of Anatomic Pathology, University of Bologna, Bellaria Hospital, Bologna, Italy.
Article Synopsis
- Heterotopia refers to the abnormal presence of salivary gland tissue in atypical locations during development, and malignant growths from these ectopic tissues are uncommon.
- A case study detailed a 66-year-old male with a neck mass, initially thought to be benign, which was later diagnosed as Secretory Carcinoma (SC) arising from heterotopic salivary gland tissue within a lymph node after surgical removal.
- This case is particularly significant as it highlights the rare occurrence of SC in heterotopic tissues, enhancing knowledge of how tumors in unusual sites behave similarly to those in normal salivary glands.
Unmasking the rarity of mammary analogue secretory carcinoma of the minor salivary gland - A case report.
Int J Surg Case Rep
November 2024
Dept. of orthodontics and dentofacial orthopaedics, M. A. Rangoonwala College of Dental Sciences & Research Centre, Pune, Maharashtra, India.
Introduction: Mammary analogue secretory carcinoma (MASC) of the salivary gland was first described by Skálová et al. in 2010. It is often associated with a translocation, t(12;15)(p13;q25), which results in the fusion gene ETV6-NTRK3.
View Article and Find Full Text PDFSecretory Carcinoma of the Thyroid: A Case Report and Update of Literature.
Head Neck Pathol
September 2024
Department of Laboratory Medicine and Pathology, Essentia Health, Fargo, ND, USA.
Primary secretory carcinoma (SC) of the thyroid gland is a rare neoplasm, characterized by the presence of oncogenic ETV6::NTRK3 fusions, which are amenable to tropomyosin receptor kinase (TRK) inhibitor therapy. Despite its morphologic, immunophenotypic, and genetic similarities to SC of the salivary and mammary glands, diagnostic pitfalls may arise in differentiating from papillary thyroid carcinoma due to overlapping features such as papillary growth, nuclear irregularity, and variable expression of PAX8. Tumor misclassification may lead to delayed consideration of molecular testing and targeted therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!